Clinical Trials
80 trialsINDIGO
Boston Scientific Corporation
Organoid Models of Hepatocellular Carcinoma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NARFI
University Hospital, Bordeaux
GRECCAR 5
University Hospital, Bordeaux
EMPOwer
University of Alberta
COOP
Dartmouth-Hitchcock Medical Center
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
IDRX, Inc., a wholly owned subsidiary of GSK, LLC
ctDNA-guided Surveillance for Stage III CRC, a Randomized Intervention Trial
University of Aarhus
ROWAN
Boston Scientific Corporation
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Pfizer
SECURE
Medtronic - MITG
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
Lesion Detection Assessment in the Liver: Standard vs Low Radiation Dose Using Varied Post-Processing Techniques
M.D. Anderson Cancer Center
Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery
M.D. Anderson Cancer Center
ALTAIR
National Cancer Center Hospital East
EPODIG-G
Centre Paul Strauss
Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions
M.D. Anderson Cancer Center
ESTANVO
Centre Francois Baclesse
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
TRIABETES
University of Pittsburgh
ARROW
Hoffmann-La Roche
A Culturally-Based Palliative Care Tele-consult Program for Rural Southern Elders
University of Alabama at Birmingham
Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
Thomas Jefferson University
Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca
Thomas Jefferson University
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OPTIMA
Imunon
Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
NanOlogy, LLC
A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Theseus Pharmaceuticals
MMOT
University Medical Center Groningen
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Kyowa Kirin Co., Ltd.
PRIORITY
Western University, Canada
Evaluate the Efficacy of Adding Intraluminal Brachytherapy After CCRT for Local-regional Thoracic Esophageal Cancer.
Taipei Veterans General Hospital, Taiwan
ASPIRIN
University Hospital, Antwerp
Efficacy and Safety of Herombopag in Patients With Thrombocytopenia Before Hepatectomy
Fudan University
Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction
Catalysis SL
Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma
Catalysis SL
Clinical Utility Evidence for TissueCypher®
Qure Healthcare, LLC
CanStem303C
Sumitomo Pharma America, Inc.
CanStem111P
Sumitomo Pharma America, Inc.
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
Sumitomo Pharma America, Inc.
EXPLORING
The First Affiliated Hospital with Nanjing Medical University
Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study
The Second Affiliated Hospital of Fujian Medical University
ALpha-T
Hoffmann-La Roche
apact
Celgene
Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma
Catalysis SL
Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy
West China Hospital
ALTER-E005
Jiangxi Provincial Cancer Hospital
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
ALTER-C-002
Zhejiang University